Journal
INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS
Volume 20, Issue 4, Pages 545-551Publisher
SPRINGER
DOI: 10.1007/s10989-014-9421-0
Keywords
Cyclic peptides; Small organic molecules; New chemical entities; Peptide therapeutics; Pharmaceutical industry
Categories
Funding
- University of Hawaii Sea Grant College Program
- USDA TSTAR [2009-34135-20067]
- HATCH [HAW00595-R]
Ask authors/readers for more resources
Studies into N- to C-terminal cyclic peptide backbone structures have provided for the lateral transition of important principles and strategies that clearly resonate within the world of bioactive peptides and peptide toxins. The ability to transform peptide biologics into stable and orally active constituents represents a major pharmacological achievement. This progression has been forthcoming and is potentially intensified by the diminishing expectations of current small organic molecule pipelines. While still in the early stages of development, cyclic peptide drug leads have gained the attention of the pharmaceutical industry, however their true potential is still very much unknown.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available